MiMedx To Present At 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Mon Dec 22, 1:28PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced the schedule for its presentation at the 33rd Annual J. P. Morgan Healthcare Conference. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, will present on Thursday, January 15, 2015, 9:00 a.m. PST, at the Westin St. Francis Hotel in San Francisco. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
JPM: 62.48 (unch), MDXG: 11.17 (+0.17)
MiMedx updates 2015 guidance
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:52AM CST
MDXG: 11.17 (+0.17)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 43.84 (+0.87), RTIX: 5.20 (unch), HALO: 9.34 (+0.31), EBS: 27.64 (+1.28), ANIK: 38.26 (+0.73), MDXG: 11.17 (+0.17)
MiMedx Raises Expectations For 2015 Revenue To Range From $175 Million To $190 Million
PR Newswire - Mon Dec 15, 7:45AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its updated outlook for 2015.
MDXG: 11.17 (+0.17)
MiMedx Group, Conn's, Mylan, Pfizer and Amgen highlighted as Zacks Bull and Bear of the Day
PR Newswire - Fri Dec 12, 8:30AM CST
Zacks Equity Research highlights MiMedx Group, Inc. (Nasdaq:MDXG-Free Report) as the Bull of the Day and Conn's (Nasdaq:CONN-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Mylan Inc. (Nasdaq:MYL-Free Report), Pfizer (NYSE
AMGN: 160.67 (+3.15), MDXG: 11.17 (+0.17)
Zacks' Bull Of The Day: MiMedx
Zacks Investment Research - Seeking Alpha - Fri Dec 12, 5:53AM CST
Today's Bull of the Day comes from biomedical/genetics industry that currently ranks in the Top 22% of our Zacks Industry Rank. If you're looking for innovation and trying to find a company with great revenue growth poised to stick around for the...
MDXG: 11.17 (+0.17)
Bull of the Day: MiMedx (MDXG) - Bull of the Day
David Bartosiak - ZACKS - Fri Dec 12, 12:00AM CST
Bull of the Day: MiMedx (MDXG) - Bull of the Day
MDXG: 11.17 (+0.17)
MiMedx To Present At The Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Thu Dec 04, 8:00AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at the Oppenheimer 25th Annual Healthcare Conference in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present on Wednesday, December 10th, 11:30 a.m. EST, at the Crowne Plaza Hotel. A webcast of this presentation will be available on the Company's website, www.mimedx.com.
MDXG: 11.17 (+0.17)
Can MiMedx Group (MDXG) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:39AM CST
MiMedx Group (MDXG) has decent short-term momentum and is seeing solid activity on the earnings estimate revision front. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on MDXG’s earnings for the coming quarter and year.
MDXG: 11.17 (+0.17)
Can MiMedx Group (MDXG) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 7:53AM CST
MiMedx Group has been witnessing a nice streak of beating earnings estimates. In fact, the company currently has a favorable Zacks Rank and a positive Earnings ESP, which is a great sign of a coming beat.
MDXG: 11.17 (+0.17)
Thirteen Poster Abstracts Chronicling The Clinical Use, Cost Effectiveness And Accelerated Healing Results of MiMedx Products to be Presented by VA Physicians at Desert Foot Conference
PR Newswire - Tue Nov 18, 7:00AM CST
MiMedx Group, Inc. (NASDAQ: MDXG) announced today that fourteen poster abstracts chronicling the Company's dehydrated human amnion/chorion membrane (dHACM) allografts to be clinically effective and cost effective in the healing of chronic wounds, difficult lower extremity wounds that have failed prior wound treatment modalities, challenging surgical wounds, chronic neuropathic wounds, wounds threatening the loss of limbs, and other hard-to-heal wounds will be presented at the 11th Annual Desert Foot High Risk Diabetic Foot Conference in Phoenix, Arizona, beginning November 19, 2014, and concluding on November 21, 2014. The abstracts describe the results of independent case studies undertaken by the presenters.
MDXG: 11.17 (+0.17)
MiMedx's Competitive Advantage And Management Execution Charts Path To Future Growth And Shareholder Opportunity
Dave Kelly - at Seeking Alpha - Tue Nov 18, 5:45AM CST
ZMH: 114.11 (+0.64), MDT: 74.08 (+0.31), MDXG: 11.17 (+0.17)
Multi-Center Comparative Study Of MiMedx EpiFix® And Organogenesis Apligraf® Determines EpiFix Has Considerably Higher Rates Of Complete Healing And Significantly Faster Time To Heal
PR Newswire - Mon Nov 17, 3:01PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that its latest peer-reviewed clinical study has been accepted for publication in the International Wound Journal.
MDXG: 11.17 (+0.17)
MiMedx elects Christopher M. Cashman as EVP
M2 - Mon Nov 10, 8:11AM CST
Regenerative medicine company MiMedx Group (NasdaqCM:MDXG) announced on Friday that it has appointed Christopher M. Cashman as its executive vice president & chief commercialisation officer.
MDXG: 11.17 (+0.17)
MiMedx® Adds New Executive
PR Newswire - Fri Nov 07, 8:39AM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Christopher M. Cashman has joined MiMedx as the Company's Executive Vice President & Chief Commercialization Officer.
MDXG: 11.17 (+0.17)
Biotech Equities Scrutiny - Vanda Pharma, PDL BioPharma, Synergy Pharma, OPKO Health, and MiMedx
PR Newswire - Fri Nov 07, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), PDL BioPharma Inc. (NASDAQ: PDLI), Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), OPKO Health Inc. (NYSE: OPK), and MiMedx Group Inc. (NASDAQ: MDXG). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, November 6, 2014, the NASDAQ Composite ended at 4,638.47, up 0.38%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,554.47, and the S&P 500 closed at 2,031.21, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 782.64, up 0.57%, with the index also advancing 11.74% in the previous three months. Register for your complimentary reports on these five stocks at:
SGYP: 3.08 (+0.12), OPK: 9.63 (+0.21), VNDA: 14.69 (+1.11), MDXG: 11.17 (+0.17), PDLI: 7.61 (unch)
MiMedx To Present At Two Healthcare Conferences
PR Newswire - Wed Nov 05, 1:59PM CST
MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that it will present at two healthcare conferences in New York, New York. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to present at the 2014 Stifel Healthcare Conference on Wednesday, November 19, 2014 at 11:30 am EST at the Palace Hotel. Management will also present at 8:00 am EST on Thursday, November 20, 2014, at the Canaccord|Genuity Forum, which is being held at the Westin Grand Central Hotel. Webcasts of each presentation will be available on the Company's website, www.mimedx.com.
MDXG: 11.17 (+0.17)
MiMedx raises full year 2014 guidance after Q3
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 5:42AM CDT
MDXG: 11.17 (+0.17)
MiMedx Group's (MDXG) CEO Parker Petit on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 4:54PM CDT
MDXG: 11.17 (+0.17)